tailieunhanh - Báo cáo y học: "Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome. | Available online http content 9 2 R43 Research article Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjogren s syndrome Peter Willeke1 Markus Gaubitz1 Heiko Schotte1 Christian Maaser1 Wolfram Domschke1 Bernhard Schluter2 and Heidemarie Becker1 Department of Medicine B Muenster University Hospital Albert Schweitzer Strasse 33 481 29 Muenster Germany institute of Clinical Chemistry and Laboratory Medicine Muenster University Hospital Albert Schweitzer Strasse 33 48129 Muenster Germany Corresponding author Peter Willeke Received 1 Mar 2007 Revisions requested 11 Apr 2007 Revisions received 16 Apr 2007 Accepted 30 Apr 2007 Published 30 Apr 2007 Arthritis Research Therapy 2007 9 R43 doi ar2182 This article is online at http content 9 2 R43 2007 Willeke et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract The objective of this study was to analyse levels of the proinflammatory cytokine macrophage migration inhibitory factor MIF in patients with primary Sjogren s syndrome pSS and to examine associations of MIF with clinical serological and immunological variables. MIF was determined by ELISA in the sera of 76 patients with pSS. Further relevant cytokines IL-1 IL-6 IL-10 IFN-y and TNF-a secreted by peripheral blood mononuclear cells PBMC were determined by ELISPOT assay. Lymphocytes and monocytes were examined flow-cytometrically for the expression of activation markers. Results were correlated with clinical and laboratory findings as well as with the HLA-DR genotype. Healthy age- and sex-matched volunteers served as controls. We found that MIF was increased in patients with pSS .